NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, will
70% in vivo editing of human APOC3 in a single administration76% triglyceride reduction after a single dose in murine disease model NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ:CLLS), a genome
LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Cellectis S.A. ("Cellectis" or the
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS). Such investors are advised to contact
BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS) investors concerning
LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS) on behalf of investors
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS). Such investors are advised to
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS). Such investors are advised to contact
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS). Such investors are advised to
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS). Such investors are advised to contact
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS). Such investors are advised to
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cellectis S.A. ("Cellectis" or "the
ATLANTA, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS) complied with federal securities laws. On
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cellectis S.A. ("Cellectis" or the "Company")
Law Offices of Howard G. Smith announces an investigation on behalf of Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ: CLLS) investors concerning the Company’s possible violations of federal
